alphagen Co., Ltd. Akimitsu Hirai President & CEO

Transcription

1 alphagen Co., Ltd. Akimitsu Hirai President & CEO 1

2 Company Profile Name of Company: alphagen Co., Ltd. Foundation: February, 2004 Head Office: Management: Technologies: Company Capitalization: Major Investors: 3-29 Kioicho, Chiyoda-ku, Tokyo, Japan President and CEO: Akimitsu Hirai Chimera sirna technology and sequencing design 100 million Yen Daiwa SMBC Capital Co., Ltd., JAFCO Co., Ltd., DAIDO LIFE INSURANCE COMPANY, The University of Tokyo Edge Capital Co., Ltd., Mitsubishi UFJ Capital Co., Ltd. and others 2

3 Management Team Akimitsu Hirai, LL.M., President and CEO Mr. Hirai is an attorney at law and patent attorney in the field of IP for about 20 years and has run Lexwell Partners for 10 years. He graduate from University of Washington (Master of Law) and Keio University doctoral course (Molecular biology). He joined alphagen at the foundation as an auditor and has involved long in this field. Yukikazu Natori, Director Mr. Natori is a founder of alphagen and Professor of Tokyo Institute of Technology. He has worked at the Mitsubishi Chemical Corporation as a director (Riji) for the biotechnology related business field. Then, he became a chairman of the board of CellFree Sciences Co. Ltd, CEO of Bio Thinktank, Co. Ltd. and advisor of RNAi, Co. Ltd. Keiji Kawamoto, Director Mr. Kawamoto is a patent attorney and has run Kawamoto Bio-business Patent Office. After graduate from Tokyo University, he joined Fujisawa Pharmaceutical, Co. Ltd. He is also a board member of Ribomic, Co. Ltd. 3

4 Basic Technologies for RNAi drug development sichimera (Owned by alphagen) RNA/DNA double-stranded oligo sidirect Tools and Algorithm for sirna design (Owned by alphagen Provided by RNAi, Co.) Other Design Tools and Algorithm for sirna design Unique Target Genes Lowered off-target effect Unique sirna Drug Development 4

5 Comparison between Tuschl chl-ii and sichimera Tuschl-II sichimera construct double stranded RNA double stranded RNA/DNA length 19~25-mer 19~25-mer 3 overhang DNA modification at least one strand has a 3'-overhang of 1-5 nucleotides 1. Claiming at least one sugar-modified ribonucleotide covering substitution of 2 -OH group with -H, does not claim substitution of T with U 2. Teaching that four (4) nucleotides from 3 -terminus could be DNAs sense With or without 3 -overhang 1. Substitution of RNA with DNA 2. Nine (9) nucleotide from 3 -end of sense and seven (7) nucleotides from 5 -enf of antisense can be replaced with DNA(as a example) sense structure antisense :RNA antisense :DNA 5

6 Advantage of sichimera over sirnai Off-target effects specificity is higher with sichimera - expected less side effects Immune reactivity Stability UGUGU-motif in ordinary sirnai activates TNF-α production but sichimera does not Lyophilized sichimera is stable: 6 months at RT & -20 Scalability, GMP production No problem with sichimera 6

7 Some case studies Pharmacological effects Confirmed using sichimera 1. anti Int6 2. PLK-1 7

8 Knockdown efficiency in vitro human Int-6 (HeLa cell) Rat Int6 (L6 rat myoblast) % o f C o t r o l sichimera sirna l o r t n o C 60 f o % 40 sichimera H 5 H 11 H R6 H M7 H 1 H 9 H 18 H MR14 H 12 H 3 H 2 H MR15 R NAi1 H 10 H 16 H 20 H MR13 H MR17 H 19 H 4 G F-1 H 8 0 2_C6 4_C6 2_C8 2_C7 3_C6 2_C5 2_C1 1_C6 4_C8 4_C1 4_C7 4_C2 1_C5 5_C6 2_C2 3_C5 Experiments sirna concentration: 5 nmol Lipofection reagent :Lipofectamine2000(Invitrogen) 48 hours after lipofection, the mrna level were assessed by quantitative RT-PCT 8

9 Microangiogram in Intermittent Claudication model saline 100μL Int6-Chimera Chimera 3mg/100μL in saline The capillaries should not be observed in microangiogram, but arteriole (more than 100 µm diameter) The arteriole network was likely generated at 2 weeks post i.m. injection of Int6-siChimera (3mg/site) Neo-capillaries might not be necessarily required for the improvement of blood flow in ischemic muscles. 9

10 GAIT Results I. Cilostazole (30mg/head) II. No treatment III. saline IV. ALG mg/site 10

11 Other models:data available under CDA Brain injury model in rats Skin wound model in diabetic mice Myocardial infarction model in rats 11

12 Embodiment of chimera patent technology targeting PLK1 * We are negotiating on the joint research and development and/or the license of PLK-1 with other major pharmaceutical companies. 12

13 13 Selection of optimum sequence

14 Effect on growth of UM-UC-3 xenograft model Tumor Volume Body Weight 4 weeks male BALB/cAJcl-nu/nu mice (n=6) were subcutaneously inoculated and transplanted with 3 x 106 of UM-UC-3 human bladder tumor cells. Treatment started when tumors reached about 100 mmmm3 in volume, approximately 2 weeks after transplantation. 5mg/kg of ALG345 or cisplatin, or saline were intravenously injected once a week. At the end of the study on the day 20, the tumor from each mouse was removed and subjected to immunohistochemical analysis. 14

15 Please contact me Akimitsu Hirai 15